Last $2.74 USD
Change Today -0.01 / -0.36%
Volume 46.1K
CPXX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 5:20 PM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

celator pharmaceuticals inc (CPXX) Snapshot

Open
$2.75
Previous Close
$2.75
Day High
$2.80
Day Low
$2.64
52 Week High
09/26/13 - $6.00
52 Week Low
04/8/14 - $2.04
Market Cap
71.5M
Average Volume 10 Days
52.9K
EPS TTM
$-0.57
Shares Outstanding
26.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELATOR PHARMACEUTICALS INC (CPXX)

Related News

No related news articles were found.

celator pharmaceuticals inc (CPXX) Related Businessweek News

No Related Businessweek News Found

celator pharmaceuticals inc (CPXX) Details

Celator Pharmaceuticals, Inc., a pharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, represents a novel approach that identifies molar ratios of drugs that would deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle, which maintains the ratio in patients with improving clinical outcomes. The company’s pipeline includes two clinical stage products, CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase II studies for the treatment of acute myeloid leukemia (AML) and a Phase III study in patients with secondary AML; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidates comprise CPX-571, a liposomal formulation of irinotecan:cisplatin; and CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for in vitro and in vivo study. The company was founded in 1999 and is headquartered in Ewing, New Jersey.

21 Employees
Last Reported Date: 03/24/14
Founded in 1999

celator pharmaceuticals inc (CPXX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $527.1K
Founder, President and Chief Scientific Offic...
Total Annual Compensation: $367.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $377.3K
Compensation as of Fiscal Year 2013.

celator pharmaceuticals inc (CPXX) Key Developments

Celator Pharmaceuticals, Inc. - Analyst/Investor Day

To discuss the company's strategic plan aimed at long-term growth, as well as provide updates on its proprietary CombiPlex(R) technology platform and an overview of lead compound CPX-351, currently in a Phase 3 clinical trial for the treatment of high-risk (secondary) acute myeloid leukemia

Celator Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-24-2014 10:30 AM

Celator Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-24-2014 10:30 AM. Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Derek Miller, Chief Business Officer.

Celator Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 02:00 PM

Celator Pharmaceuticals, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 02:00 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Fred M. Powell, Chief Financial Officer, Principal Accounting Officer and Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPXX:US $2.74 USD -0.01

CPXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPXX.
View Industry Companies
 

Industry Analysis

CPXX

Industry Average

Valuation CPXX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELATOR PHARMACEUTICALS INC, please visit www.celatorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.